SG11202000069XA - Novel anti-human ceacam5 antibody fab fragment - Google Patents

Novel anti-human ceacam5 antibody fab fragment

Info

Publication number
SG11202000069XA
SG11202000069XA SG11202000069XA SG11202000069XA SG11202000069XA SG 11202000069X A SG11202000069X A SG 11202000069XA SG 11202000069X A SG11202000069X A SG 11202000069XA SG 11202000069X A SG11202000069X A SG 11202000069XA SG 11202000069X A SG11202000069X A SG 11202000069XA
Authority
SG
Singapore
Prior art keywords
fab fragment
cancer
human ceacam5
antibody fab
ceacam5 antibody
Prior art date
Application number
SG11202000069XA
Inventor
Hitoshi Doihara
Kazunori Hirayama
Hiroki Shirai
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of SG11202000069XA publication Critical patent/SG11202000069XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

NOVEL ANTI-HUMAN CEACAM5 ANTIBODY FAB FRAGMENT Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
SG11202000069XA 2017-07-07 2018-07-06 Novel anti-human ceacam5 antibody fab fragment SG11202000069XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017133698 2017-07-07
PCT/JP2018/025618 WO2019009388A1 (en) 2017-07-07 2018-07-06 Novel anti-human ceacam5 antibody fab fragment

Publications (1)

Publication Number Publication Date
SG11202000069XA true SG11202000069XA (en) 2020-02-27

Family

ID=64950161

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000069XA SG11202000069XA (en) 2017-07-07 2018-07-06 Novel anti-human ceacam5 antibody fab fragment

Country Status (18)

Country Link
US (1) US11667724B2 (en)
EP (1) EP3650470A4 (en)
JP (1) JP7080002B2 (en)
KR (1) KR102665275B1 (en)
CN (1) CN110831977B (en)
AU (1) AU2018296644A1 (en)
BR (1) BR112020000274A2 (en)
CA (1) CA3068691A1 (en)
CO (1) CO2020000517A2 (en)
IL (1) IL271701A (en)
JO (1) JOP20200002A1 (en)
MA (1) MA51029A (en)
PH (1) PH12020500058A1 (en)
SG (1) SG11202000069XA (en)
TW (1) TWI795415B (en)
UA (1) UA126921C2 (en)
WO (1) WO2019009388A1 (en)
ZA (1) ZA202000219B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058689T2 (en) 2016-11-18 2022-09-28 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
MX2021004146A (en) * 2018-10-10 2021-06-08 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex.
EP3981793A4 (en) * 2019-06-04 2023-06-07 Biotheus Inc. Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof
CA3188862A1 (en) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions and methods for treating mesothelin positive cancers
JP2023538115A (en) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Compositions and methods for treating CEACAM-positive cancers

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO2000066160A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
US20020146750A1 (en) 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
DE10303664A1 (en) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Detection molecules for the treatment and detection of tumors
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
BRPI0614100A2 (en) 2005-08-03 2011-03-09 Immunogen Inc liquid immunoconjugate formulations
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
JP2010505775A (en) 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Production of cancer-specific immune response against MUC1 and cancer-specific MUC1 antibody
EP2351777B1 (en) 2008-10-28 2015-10-28 Shionogi&Co., Ltd. Anti-muc1 antibody
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN101607985B (en) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 Monoclonal antibody for anti-human CEA, a composition containing same and application thereof
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
CN102712921B (en) 2009-09-24 2017-03-01 株式会社遗传科技 Specifically it is used for humanized antibody of aminoacid sequence RGD of extracellular matrix protein and application thereof
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2565268A4 (en) 2010-04-28 2013-10-09 Shionogi & Co Novel muc1 antibody
CN101928347B (en) * 2010-05-05 2013-03-27 上海海抗中医药科技发展有限公司 Anti-carcinoembryonic-antigen (CEA) antibody and application thereof
SG10201506030RA (en) 2010-07-30 2015-09-29 Medimmune Llc Method for purifying active polypeptides or immunoconjugates
CA2827722C (en) * 2011-03-02 2020-05-12 Roche Glycart Ag Anti-cea antibodies
JP6164556B2 (en) 2011-12-01 2017-07-19 国立大学法人 千葉大学 Drug for producing radiolabeled polypeptide with reduced nonspecific renal accumulation
RS60043B1 (en) 2012-11-20 2020-04-30 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
WO2014133093A1 (en) 2013-02-28 2014-09-04 独立行政法人国立がん研究センター Antibody against insoluble fibrin
TWI679019B (en) 2013-04-29 2019-12-11 法商賽諾菲公司 Anti-il-4/anti-il-13 bispecific antibody formulations
HUE056325T2 (en) 2013-08-26 2022-02-28 Biontech Res And Development Inc Nucleic acids encoding human antibodies to sialyl-lewis a
TWI541022B (en) 2013-12-18 2016-07-11 應克隆公司 Compounds to fibroblast growth factor receptor-3 (fgfr3) and methods of treatment
CA2942150A1 (en) 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
RU2016144178A (en) 2014-04-28 2018-05-10 Медисинал Кемистри Фармасьютикалс, Ко., Лтд. ANTI-BODY AGAINST MUC1 OR ITS ANTIGEN-BINDING Fragment AND ITS APPLICATION
TWI705827B (en) 2014-11-07 2020-10-01 瑞士商諾華公司 Methods for treating ocular diseases
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017150549A1 (en) 2016-03-01 2017-09-08 国立大学法人 千葉大学 Radiolabeled drug
HUE058689T2 (en) 2016-11-18 2022-09-28 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
US10758632B2 (en) 2017-02-06 2020-09-01 City Of Hope NIR-conjugated tumor-specific antibodies and uses thereof
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
EP3689892A4 (en) 2017-09-26 2021-05-12 National University Corporation Chiba University Radioactive drug
KR20210011941A (en) 2018-05-17 2021-02-02 아스텔라스세이야쿠 가부시키가이샤 Complex comprising anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
MX2021004146A (en) 2018-10-10 2021-06-08 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex.
JOP20210183A1 (en) 2019-01-07 2023-01-30 Astellas Pharma Inc Conjugate comprising ligand and ceacam5 antibody fab fragment

Also Published As

Publication number Publication date
AU2018296644A1 (en) 2020-01-23
RU2020105654A (en) 2021-08-09
JOP20200002A1 (en) 2020-01-06
CO2020000517A2 (en) 2020-01-31
US20200123270A1 (en) 2020-04-23
CN110831977A (en) 2020-02-21
JPWO2019009388A1 (en) 2020-05-07
CN110831977B (en) 2023-06-09
EP3650470A1 (en) 2020-05-13
BR112020000274A2 (en) 2020-07-14
KR20200026185A (en) 2020-03-10
CA3068691A1 (en) 2019-01-10
TW201920273A (en) 2019-06-01
MA51029A (en) 2021-03-24
US11667724B2 (en) 2023-06-06
ZA202000219B (en) 2021-08-25
KR102665275B1 (en) 2024-05-13
RU2020105654A3 (en) 2021-10-29
IL271701A (en) 2020-02-27
EP3650470A4 (en) 2021-03-24
TWI795415B (en) 2023-03-11
UA126921C2 (en) 2023-02-22
WO2019009388A1 (en) 2019-01-10
PH12020500058A1 (en) 2020-09-28
JP7080002B2 (en) 2022-06-03

Similar Documents

Publication Publication Date Title
SG11202000069XA (en) Novel anti-human ceacam5 antibody fab fragment
CY1121900T1 (en) HUMANIZED ANTI-KALLIKREIN-2 ANTIBODY
CY1124771T1 (en) ANTI-SORTILINE ANTIBODIES AND METHODS OF USING THEM
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA201592006A1 (en) NEW BISPECIFIC BINDING MOLECULES WITH ANTI-TUMOR ACTIVITY
MX2020008030A (en) Glypican 3 antibodies and conjugates thereof.
JOP20190103B1 (en) Novel anti-human muc1 antibody fab fragment
PE20161096A1 (en) DIRECTED INHIBITION OF THE TRANSFORMING GROWTH FACTOR ß (TGFß)
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2010004910A (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers.
NZ594682A (en) Fully human antibodies specific to cadm1
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
MX2021002690A (en) Anti-avb8 antibodies and compositions and uses thereof.
PH12018502293A1 (en) Humanized anti-basigin antibodies and the use thereof
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
MX2020003193A (en) Multivalent mono- or bispecific recombinant antibodies for analytic purpose.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
PH12016501579A1 (en) Novel anti-presepsin antibody
MX2020012351A (en) COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY Fab FRAGMENT, PEPTIDE LINKER AND/OR LIGAND.
EA202190304A1 (en) CHIMERIC RECEPTORS TO STEAP1 AND METHODS FOR THEIR APPLICATION
MX2021000797A (en) Cd226 agonist antibodies.